Revolo Biotherapeutics Enters into Partnership Agreement with Northway Biotech to Manufacture its Novel Binding Immunoglobulin Protein, '1805, to Support Phase 2 Trials in Rheumatoid Arthritis and Uveitis
NEW ORLEANS and LONDON and WALTHAM, Mass. and VILNIUS, Lithuania, June 09, 2021 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, announced today that it has entered into a partnership with Northway Biotech, a global end-to-end biopharmaceutical contract development and manufacturing organization (CDMO), to manufacture its binding immuno-regulatory protein, ‘1805.
Under the terms of the agreement, Northway will provide the full scope of its’ services ranging from cell line development to batch production of ‘1805 Active Pharmaceutical Ingredients (API) and drug product, following Current Good Manufacturing Practices (cGMP), with quality assurance and regulatory compliance support.
“Northway is the ideal partner for our manufacturing needs. Their expertise in cell fermentation, protein characterization and global outreach will enable our upcoming phase 2 clinical trials for ‘1805. The close collaboration between the two organizations will provide a seamless progression from our current drug supply and future process and formulation advancements,” said Jonathan Rigby, Group Chief Executive Officer of Revolo Biotherapeutics.
Vladas Algirdas Bumelis, Chief Executive Officer and Chairman of the Board of Northway Biotech, commented, “We are excited to announce our partnership with Revolo Biotherapeutics for the development and manufacturing of ‘1805. Northway Biotech’s global teams in Waltham, US, and Vilnius, Lithuania will closely collaborate with Revolo Biotherapeutics to expedite success in bringing this first-in-class therapy for patients with rheumatoid arthritis and non-infectious uveitis to market quickly and efficiently.”
Rose Rhomberg, Business Development Director of Northway Biotech, added, “Teamwork has been the cornerstone of Revolo Biotherapeutics and Northway Biotech’s partnership with the goal of delivering drug substance and product for toxicology studies and clinical trials. Our partnership will swiftly move the projects forward to bnefit patients with inflammatory and autoimmune diseases.”
About Revolo Biotherapeutics
For further information, please visit www.revolobio.com.
About Northway Biotech - https://www.northwaybiotech.com
Revolo Bio Company Contact
Revolo Bio Media Contact
Northway Biotech Contact